42
Participants
Start Date
June 26, 2017
Primary Completion Date
December 1, 2022
Study Completion Date
January 20, 2023
ONO-7475 3mg once daily
Part A initial dose level
ONO-7475 6mg once daily
Part A 2nd dose level
ONO-7475 10mg once daily
Part A 3rd dose level
ONO-7475 6mg + Venetoclax (70-400mg)
Part D ONO-7475 + Venetoclax Combination
Weill Medical College of Cornell University, New York
Thomas Jefferson University, Philadelphia
Wake Forest University, Winston-Salem
Medical University of South Carolina - Hollins Cancer Center, Charleston
The Winship Cancer Institute Emory University, Atlanta
Augusta University Medical Center, Augusta
Mayo Clinic - Jacksonville, Jacksonville
University of Florida (UF) - Shands Cancer Center, Gainesville
Norton Cancer Institute, Louisville
The Ohio State University (OSU), Columbus
University of Michigan, Ann Arbor
MD Anderson Cancer Center, Houston
University of Utah - Huntsman Cancer Institute, Salt Lake City
University of Southern California, Los Angeles
University of California, Los Angeles
Yale University School of Medicine - Yale Cancer Center, North Haven
Lead Sponsor
Ono Pharmaceutical Co. Ltd
INDUSTRY